Bala Taila Matra Basti in the management of Mootraghata(Benign Prostatic Hyperplasia
- Conditions
- Benign prostatic hyperplasia without lower urinary tract symptoms. Ayurveda Condition: MUTRAGHATAH,
- Registration Number
- CTRI/2020/12/030110
- Lead Sponsor
- Institute for Post Graduate Teaching and Research in Ayurveda Gujrat Ayurved University
- Brief Summary
In the clinical study, atotal of 40 patients with BPH were selected and divided randomly into twogroups In group-A treated with *VarunashigravaadiGhanavati* with *Bala Taila Matra* and In group B was treated with CapsuleTamsulosin (0.4 mg) orally. Both groups divided according to acomputer-generate randomization chart among them 40 patients completed thetreatment as well as follow up. All the patients were assessed as persubjective and objective criteria adopted during the study and the findingswere recorded in the research proforma.
In group-A *Varunashigravaadi Ghanavati* with *BalaTaila Matra Basti*, highly significant result was observed in average urineflow rate (UFR), enlarged prostate size & volume whereas no significantresult was found in post voidal residual urine (PVRU) volume.
Ingroup B Capsule Tamsulosin (0.4 mg) orally, highly significant result was observedin Objective parameters i.e., average urine flow rate (UFR), size of theenlarged prostate & prostate volume, and post voidal residual urine (PVRU) volume.
Statistically,a significant result was noted on Subjective Parameter i.e. increasedfrequency, nocturia, weak stream, incomplete voiding, and urgency in thepatients of both groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 40
The patients between 50-70 years of age The patients having 3 or more than 3 signs and symptoms of Mootraghata(Benign Prostatic Hyperplasia) Controlled Hypertension (BP less than 150-90 mmHg), diabetes mellitus (RBS less than 140 mg/dl).
Patients of age below 50 years and above 70 years Patients of malignancy, congenital deformities of urogenital tract or any abdominal-pelvic pathology other than BPH Systemic diseases like chronic renal failure (CRF), Uncontrolled Hypertension (BP>150-90), diabetes mellitus (RBS >140) Patients having Hematuria(Blood in the urine) , Bladder infection(UTI), kidney stone, Bladder stone PSA level above 4.0 ng/ml Patients k/c/o Tuberculosis, Paralysis, and Parkinsonism will be excluded Known case of cardiac diseases (H/o- MI, IHD).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prostate size reduced 4 weeks decrease in PSA level 4 weeks
- Secondary Outcome Measures
Name Time Method Improvement in sign and symptoms of BPH and also improvement in quality of life 4 weeks
Trial Locations
- Locations (1)
Institute for Post Graduate Teaching and Research in Ayurveda GAU Jamnagar 361008
🇮🇳Jamnagar, GUJARAT, India
Institute for Post Graduate Teaching and Research in Ayurveda GAU Jamnagar 361008🇮🇳Jamnagar, GUJARAT, IndiaAshish J TalsaniyaPrincipal investigator7984969783ajtalsaniya32@gmail.com